Dexmedetomidine
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Dexmedetomidine
- Pharmacist Assessment Report
- Dexmedetomidine: From Sedation (Original Indication Not Specified in Licence Data) to nephrogenic syndrome of inappropriate antidiuresis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Dexmedetomidine: From Sedation (Original Indication Not Specified in Licence Data) to nephrogenic syndrome of inappropriate antidiuresis
One-Sentence Summary
Dexmedetomidine is an alpha-2 adrenergic agonist marketed in India as an injectable. It is used for sedation, although the licence data compiled for this report contain no approved indication text. The TxGNN model’s top-ranked prediction is nephrogenic syndrome of inappropriate antidiuresis, but this has no supporting evidence and a weak mechanistic rationale. The best-supported direction is headache disorder (rank 4), with 4 related clinical trials (3 of them on post-dural puncture headache) and 2 randomized trials plus 1 systematic review in the literature.
Note: The sections below follow the top-ranked prediction as required by the report format. A short comparison with the better-supported headache and migraine predictions is included in the conclusion.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence data (injectable dexmedetomidine is generally used for sedation) |
| Predicted New Indication | Nephrogenic syndrome of inappropriate antidiuresis |
| TxGNN Prediction Score | 0.9960 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (16 of 16) – CDSCO approval status is not included in this data |
| Number of Listed Products | 16 (valid: 16) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Dexmedetomidine is a selective alpha-2 adrenergic agonist. This class can suppress vasopressin release and promote water excretion (aquaresis), which is the only conceptual link to a condition of excess antidiuresis.
However, nephrogenic SIAD is caused by gain-of-function mutations in the vasopressin V2 receptor (AVPR2), which act downstream of vasopressin secretion. Lowering vasopressin would not be expected to correct a receptor-level defect. The mechanistic rationale is therefore weak, and the prediction is likely a model artifact.
Clinical Trial Evidence
Currently no related clinical trials registered for nephrogenic syndrome of inappropriate antidiuresis.
For context, trials found for the better-supported predictions:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04910477 | Phase 3 | Completed | 90 | Nebulized dexmedetomidine vs neostigmine/atropine vs saline for post-dural puncture headache after cesarean section (headache disorder) |
| NCT04327726 | NA | Completed | 43 | Nebulized dexmedetomidine for post-dural puncture headache in parturients (headache disorder) |
| NCT06470854 | NA | Completed | 50 | Nebulized dexmedetomidine vs bilateral greater occipital nerve block for post-dural puncture headache (headache disorder) |
| NCT07769255 | NA | Recruiting | 146 | Nebulized dexmedetomidine on central sensitization and chronification in migraine (migraine disorder) |
Literature Evidence
Currently no related literature available for nephrogenic syndrome of inappropriate antidiuresis.
For context, the main publications for the headache disorder prediction:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36651373 | 2023 | RCT | Minerva Anestesiol | Nebulized dexmedetomidine vs neostigmine/atropine for post-dural puncture headache after cesarean section |
| 33993346 | 2021 | RCT | J Anesth | Nebulized dexmedetomidine added to conservative PDPH management, with cerebral hemodynamics assessed by transcranial Doppler |
| 41120897 | 2025 | Systematic review | BMC Anesthesiol | Meta-analysis of efficacy and safety of nebulized dexmedetomidine for PDPH after cesarean delivery |
| 39799300 | 2025 | Case report | BMC Anesthesiol | Two cases of obstetric PDPH treated with nebulized dexmedetomidine |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 58943 | Dextomid 50mcg Injection | Vial of 1 ml injection | Not stated |
| 69363 | Dexglan 100mcg Injection | Vial of 2 ml injection | Not stated |
| 59924 | Dextomid 200mcg Injection | Vial of 2 ml injection | Not stated |
| 244099 | Xamdex 100mcg Injection | Vial of 2 ml injection | Not stated |
| 146844 | Medetofix 100 Injection | Ampoule of 1 ml injection | Not stated |
There are 16 valid single-ingredient registrations in total, all injectable.
Safety Considerations
- Knowledge-graph contraindication signals (from drug-disease links, not label text): hypertensive disorder, hypertension, kidney disease, pyoureter, liver disease, gallbladder disease, diabetes mellitus, diabetic ketoacidosis, hypotensive disorder, atrioventricular block.
- Drug Interactions: 59 interactions were recorded. Moderate-level interactions include morphine (including liposomal), opium, dronabinol, nabilone, diphenoxylate, papaverine, sibutramine, ethanol, amyl nitrite, diazoxide and phentolamine. This is consistent with additive sedative or blood-pressure effects. Several others (e.g., pantoprazole, vancomycin, atropine) are of unknown severity.
- For brainstem-related headache subtypes, sedative and bradycardic effects could confound neurological assessment.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (nephrogenic SIAD) rests on a model score alone, with no trials or literature, and the mechanism is contradicted by the receptor-level cause of the disease. By contrast, headache disorder (L2, Research Question) has completed trials and two RCTs, but this evidence is limited to post-dural puncture headache, a secondary headache with distinct pathophysiology, so it does not support primary headache disorders. Migraine (L5, Research Question) has one recruiting trial (N=146) and only hypothesis-level support.
To proceed, the following is needed:
- India package insert warnings, contraindications and approved indications (a blocking data gap for safety screening)
- Mechanism of action data from DrugBank
- For headache: a larger multicentre confirmatory RCT of nebulized dexmedetomidine in post-dural puncture headache, and results from the migraine trial NCT07769255
- Route compatibility assessment: all Indian products are injectables, while the headache and migraine evidence uses a nebulized route
- No further work on nephrogenic SIAD unless a credible mechanistic or preclinical rationale emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.